Literature DB >> 12942698

Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis.

M D Posthumus1, P C Limburg, J Westra, M A van Leeuwen, M H van Rijswijk.   

Abstract

OBJECTIVE: To evaluate serum matrix metalloproteinase 3 (MMP-3) levels in comparison to C-reactive protein (CRP) in periods with and without progression of radiological damage in patients with early rheumatoid arthritis (RA).
METHODS: Thirty-two patients with RA and radiological progression (> or = 5 points according to the Sharp/van der Heijde method) during 6 months followed by a 6-month period without radiological progression (< or = 1 point) were selected from a prospective follow-up study of early RA patients. Serum MMP-3 levels, CRP, the erythrocyte sedimentation rate (ESR), disease activity index (DAS), swollen joint count (SJC), tender joint count (TJC), and Ritchie articular index (RAI) were measured monthly and results were transformed into mean values for the 6-month periods.
RESULTS: During the period with radiological progression the mean serum MMP-3 correlated significantly with the mean CRP (r = 0.68, p < 0.001), ESR (r = 0.54, p = 0.001) and swollen joint count (r = 0.48, p = 0.006). In the period without radiological progression the mean serum MMP-3 only correlated with the mean CRP (r = 0.44, p = 0.012). Individual changes--expressed in percentages (%)--between the two periods showed a decrease in both the mean serum MMP-3 and CRP in 19 and an increase in 3 patients, in parallel with other markers of disease activity in these patients (69% of cases). The individual change (%) in mean serum MMP-3 or CRP did not correlate with the difference in radiological progression between the two periods.
CONCLUSIONS: Serum MMP-3 and CRP are closely related and there seems to be no difference between serum MMP-3 and CRP with regard to the monitoring of the progression of radiological damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942698

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study.

Authors:  Slavica Z Prodanovic; Goran Radunovic; Dragan Babic; Biljana Ristic; Mirjana Sefik-Bukilica; Maja Zlatanovic; Katarina Simic-Pasalic; Srdjan Seric; Nada Vujasinovic-Stupar; Janko Samardzic; Nemanja Damjanov
Journal:  Med Princ Pract       Date:  2018-05-24       Impact factor: 1.927

Review 2.  TRPV4 as a therapeutic target for joint diseases.

Authors:  Amy L McNulty; Holly A Leddy; Wolfgang Liedtke; Farshid Guilak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-18       Impact factor: 3.000

Review 3.  Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity?

Authors:  Licia Maria Henrique da Mota; Leopoldo Luiz dos Santos Neto; Jozélio Freire de Carvalho
Journal:  Clin Rheumatol       Date:  2009-07-14       Impact factor: 2.980

4.  Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.

Authors:  Aşkin Ateş; Nuran Türkçapar; Umit Olmez; Olcay Tiryaki; Nurşen Düzgün; Emre Uğuz; Murat Duman
Journal:  Rheumatol Int       Date:  2007-04-11       Impact factor: 3.580

5.  Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis.

Authors:  Sylvia Dörr; Nadine Lechtenböhmer; Rolf Rau; Gertraud Herborn; Ulf Wagner; Bertram Müller-Myhsok; Ingo Hansmann; Gernot Keyszer
Journal:  Arthritis Res Ther       Date:  2004-03-08       Impact factor: 5.156

6.  Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.

Authors:  Jean C Rousseau; Eren U Sumer; Gert Hein; Bodil C Sondergaard; Suzi H Madsen; Christian Pedersen; Thomas Neumann; Andreas Mueller; Per Qvist; Pierre Delmas; Morten A Karsdal
Journal:  BMC Musculoskelet Disord       Date:  2008-05-28       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.